Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy

Citation

Gamble, L. J.; Borovjagin, A. V.; & Matthews, Q. L. (2010). Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy. Experimental and Therapeutic Medicine, 1(2), 233-240.

Abstract

The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.

Keyword(s)

adenovirus
alpha(v)beta(3) integrin
alpha-v integrins
arginine-glycine-aspartate
capsid protein-ix
coxsackievirus-adenovirus receptor
enhanced infectivity
extracellular-matrix
growth-factor receptor
human-melanoma cells
in-vivo
integrin
mediated gene-transfer
ovarian cancer
targeted therapy
virotherapy

Notes

687XM
Times Cited:1
Cited References Count:122

Reference Type

Journal Article

Secondary Title

Experimental and Therapeutic Medicine

Author(s)

Gamble, L. J.
Borovjagin, A. V.
Matthews, Q. L.

Year Published

2010

Volume Number

1

Issue Number

2

Pages

233-240

ISSN/ISBN

1792-0981

DOI

Doi 10.3892/Etm_00000037